share_log

Avenue Therapeutics | 8-K: Current report

Avenue Therapeutics | 8-K: Current report

Avenue Therapeutics | 8-K：重大事件
美股SEC公告 ·  05/13 12:36
Moomoo AI 已提取核心信息
On May 10, 2024, Avenue Therapeutics, Inc. announced the entry into an At the Market Offering Agreement with H.C. Wainwright & Co. LLC, enabling the company to offer and sell shares of its common stock at its discretion. The shares will be sold pursuant to a shelf registration statement effective since December 10, 2021, with a prospectus supplement filed on the same date as the agreement. The company may sell up to $3,850,000 of its shares under this agreement, with H.C. Wainwright & Co. LLC acting as the sales agent. The sales agent will receive a 3.0% commission on gross proceeds and be reimbursed for certain expenses. Both parties have the right to terminate the agreement upon prior written notice, and the company is not obligated to sell any shares. The offering will conclude upon the sale of all shares or termination of the agreement. The details of the agreement were outlined in a Current Report on Form 8-K filed with the SEC, accompanied by legal opinions from Troutman Pepper Hamilton Sanders LLP.
On May 10, 2024, Avenue Therapeutics, Inc. announced the entry into an At the Market Offering Agreement with H.C. Wainwright & Co. LLC, enabling the company to offer and sell shares of its common stock at its discretion. The shares will be sold pursuant to a shelf registration statement effective since December 10, 2021, with a prospectus supplement filed on the same date as the agreement. The company may sell up to $3,850,000 of its shares under this agreement, with H.C. Wainwright & Co. LLC acting as the sales agent. The sales agent will receive a 3.0% commission on gross proceeds and be reimbursed for certain expenses. Both parties have the right to terminate the agreement upon prior written notice, and the company is not obligated to sell any shares. The offering will conclude upon the sale of all shares or termination of the agreement. The details of the agreement were outlined in a Current Report on Form 8-K filed with the SEC, accompanied by legal opinions from Troutman Pepper Hamilton Sanders LLP.
2024年5月10日，Avenue Therapeutics, Inc.宣布与H.C. Wainwright & Co.签订市场发行协议。有限责任公司，使公司能够自行决定发行和出售其普通股。股票将根据自2021年12月10日起生效的上架注册声明出售，招股说明书补充文件将与协议同日提交。根据该协议，该公司可能与H.C. Wainwright & Co.出售高达385万美元的股份。有限责任公司充当销售代理。销售代理将获得总收益的3.0％的佣金，并报销某些费用。双方都有权在事先书面通知后终止协议，公司没有义务出售任何股票。本次发行将在出售所有股份或终止协议时结束。向美国证券交易委员会提交的关于8-K表的最新报告概述了该协议的细节，并附有特劳特曼·佩珀·汉密尔顿·桑德斯律师事务所的法律意见。
2024年5月10日，Avenue Therapeutics, Inc.宣布与H.C. Wainwright & Co.签订市场发行协议。有限责任公司，使公司能够自行决定发行和出售其普通股。股票将根据自2021年12月10日起生效的上架注册声明出售，招股说明书补充文件将与协议同日提交。根据该协议，该公司可能与H.C. Wainwright & Co.出售高达385万美元的股份。有限责任公司充当销售代理。销售代理将获得总收益的3.0％的佣金，并报销某些费用。双方都有权在事先书面通知后终止协议，公司没有义务出售任何股票。本次发行将在出售所有股份或终止协议时结束。向美国证券交易委员会提交的关于8-K表的最新报告概述了该协议的细节，并附有特劳特曼·佩珀·汉密尔顿·桑德斯律师事务所的法律意见。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息